Gene therapy promises to be one of the most important frontiers in medicine. Although no significant achievements for curing disease have been achieved, the future seems to hold significant potential in terms of developing such approaches. By the year 2015, global market for gene therapy is projected to reach $484 million.
San Jose, CA (PRWEB) November 4, 2008 -- Advancements in gene therapy have provided useful data, which has helped in understanding the pathogenesis of diseases. The discipline heralds a significant potential for the biotechnology industry over the next 20 years, as the approach moves from research labs to clinical trials. Proteins and monoclonal antibodies have revolutionized the treatment of a wide variety of diseases, and gene-based therapies that deliver the DNA sequences encoding proteins and antibodies signify the next big step in the evolution of biopharmaceuticals.
Gene therapy market is still in the experimental stages with success yet to be achieved in developing completely curative therapeutic drugs, as stated in a recent report published by Global Industry Analysts, Inc. Till date, only one gene therapy drug Gendicine, developed by Shenzhen SiBiono Gene Technologies Co., has been approved, which is marketed in China. Market predictions for gene therapy highly depend on the regulatory approval of products currently in clinical trials. Most gene therapy products for cancer and cardiovascular diseases are in Phase III/ Phase II of clinical trials. Cost of the treatment and disease population are the other factors that affect the gene therapy market. Funding and research developments and acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future.
Gene therapy industry comprises of biotech, pharmaceutical companies, research, and academic institutions. Leading biotech companies operating in gene therapy marketplace include AnGes MG Inc, Cell Genesys, GenVec, Genzyme Corporation, Introgen Therapeutics Inc, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd, Targeted Genetics Corp, Transgene, Urigen Pharmaceuticals Inc., and Vical.
The report, titled "Gene Therapy: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides comprehensive insight into the industry dynamics, and highlights noteworthy market drivers, challenges, and trends shaping the market. The report also enumerates recent industry developments, and outlines the gene therapy products under development. Analysis is provided for the period 2007-2015.
For more details about this research report, please visit http://www.strategyr.com/Gene_Therapy_Market_Report.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Email press @ StrategyR.com
Web Site http://www.StrategyR.com/
Read the full story at http://www.prweb.com/releases/gene_therapy/biotechnology/prweb1563264.htm
Copyright©2008 Vocus, Inc.
All rights reserved